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Markus Bo¨hm1, Thomas A. Luger1, Desmond J. Tobin2 and Jose´ Carlos Garcı´a-Borro´n3
The melanocortin (MC) system is probably the best characterized neuropeptide network of the skin. Most
cutaneous cell types express MC receptors (MC-Rs) and synthesize MCs, such as a-melanocyte-stimulating
hormone (a-MSH), that act in autocrine and paracrine fashion. In human skin cells, activation of adenylate
cyclase by MCs occurs at 106–109 M doses of the ligand, but effects are induced in some cell types at
subnanomolar concentrations. In addition to the pigmentary action of MCs on epidermal melanocytes, the hair
follicle is a source and target for MCs. MCs regulate lipogenesis in sebocytes expressing both MC-1R and MC-
5R. In adipocytes, lipid metabolism is modulated by agouti signalling protein, a natural MC-1R/MC-4R
antagonist. The anti-inflammatory activity of a-MSH includes immunomodulatory effects on several resident
skin cells and antifibrogenic effects mediated via MC-1R expressed by dermal fibroblasts. In human mast cells,
a-MSH appears to be proinflammatory due to histamine release. a-MSH exhibits cytoprotective activity against
UVB-induced apoptosis and DNA damage, a finding that helps explain the increased risk of cutaneous
melanoma in individuals with loss of function MC-1R mutations. These findings should improve our
understanding of skin physiology and pathophysiology and may offer novel strategies with MCs as future
therapeutics for skin diseases.
Journal of Investigative Dermatology (2006) 126, 1966–1975. doi:10.1038/sj.jid.5700421
Introduction
Melanocortins (MCs), originally char-
acterized as regulators of pigmentation
and of cortisol production, are structu-
rally related peptides involved in an
ever-increasing list of additional pro-
cesses such as food intake, energy
homeostasis, sexual behavior, exocrine
gland function, inflammatory re-
sponses, and others (Gantz and Fong,
2003). The natural MCs, ACTH and
the melanocyte-stimulating hormones
(a-, b-, and g-MSH), derive from pro-
opiomelanocortin (POMC), which is
processed by distinct members of the
prohormone convertase family (Seidah
et al., 1999) (Figure 1).
It is now established that human
skin is a potent source for MCs (Thody
et al., 1983; Slominski et al., 1993;
Slominski et al., 2000b). Most cuta-
neous cell types express POMC, pro-
hormone convertases, and release MCs
in vitro (Chakraborty et al., 1996;
Peters et al., 2000; Schiller et al.,
2001; Bo¨hm et al., 2005a; Kauser
et al., 2005). Expression of MCs and
of cortisol by the skin is orchestrated by
pro-inflammatory stimuli and cortico-
tropin-releasing hormone analogous to
regulation of the central MC system
(Slominski et al., 2000a, 2001,
2005c, d; Ito et al., 2005). Since vir-
tually all cutaneous cell types exam-
ined so far not only synthesize MCs but
also express MC receptors (MC-Rs), the
cutaneous MC system is a complex
endocrine, paracrine, and autocrine
network.
In this review, we will summarize
the latest findings on the cutaneous MC
system. Emphasis in this collection of
data is on the human system and on
novel functional data providing the
reader with deeper insight into cuta-
neous physiology and indicating future
perspectives for therapeutic interven-
tion with MC peptides. Owing to space
limitations of this review, it was im-
possible to list all cited references in
the print version of this review. The
interested reader can access the addi-
tional references in the Supplementary
material.
Biochemistry and pharmacology of
melanocortin receptors
The five MC-Rs that have been cloned
and characterized belong to the G
protein-coupled receptors superfamily
(Starowicz and Przewlocka, 2003).
They are integral membrane proteins
with an extracellular N-terminus, seven
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transmembrane fragments, and an intra-
cellular C-terminus. Members of the
MC-R subfamily are regulated by both
endogenous MC agonists and the natur-
al peptide antagonists Agouti signal
protein (ASP) and agouti-related peptide
(AGRP). The MC-Rs display overlapping
specificities and usually bind several
MCs. Only MC-2R shows a strong
selectivity for ACTH (Mountjoy et al.,
1992). Human MC-1R (Sanchez-Mas
et al., 2004) and MC-4R (Gantz et al.,
1993a) discriminate poorly between
ACTH. a-MSH in murine Mc-1r is more
potent than ACTH. a-MSH is the pre-
ferred, though not exclusive, MC-5R
ligand, while MC-3R is the least selec-
tive receptor of the family (Gantz et al.,
1993b; Roselli-Rehfuss et al., 1993;
Labbe et al., 1994). Attempts have been
made to design subtype-specific MC-Rs
agonists and antagonists (Holder and
Haskell-Luevano, 2004). Recently, non-
peptide MC-1R agonists have been
reported (Haskell-Luevano et al., 1999;
Bondebjerg et al., 2002; Herpin et al.,
2003). Concerning the mechanisms of
receptor activation, docking models
developed for MC-1R and MC-4R sug-
gest that a charged domain, containing
conserved acidic residues in transmem-
brane2 and transmembrane3 (Glu94,
Asp117, and Asp121 in MC-1R), inter-
acts with the Arg residue in the His-Phe-
Arg-Trp pharmacophore core shared by
natural MCs. Site-directed mutagenesis
of the MC-1R and MC-4R has also
defined the recognition sites of the fully
active antagonistic peptides ASP90-132
and AGRP86-132 (Chai et al., 2005). In
AGRP (antagonistic to MC-3R and MC-
4R) receptor recognition is localized to
a 34 residue allowing the design of a
fully active mini-AGRP and the devel-
opment of chimera proteins with potent
agonist activity by grafting agonist pep-
tides into the mini-AGRP active loop
(Jackson et al., 2005).
MC-Rs undergo post-translational
processing and traffic from the endo-
plasmic reticulum, where they are
synthesized, to the plasma membrane.
For MC-1R and other MC-Rs, co-
translational and post-translational
modifications include glycosylation
(Sanchez-Mas et al., 2002), acylation
(Frandberg et al., 2001; Sanchez-Mas
et al., 2005b), and disulfide bond
formation (Frandberg et al., 2001; Holst
et al., 2002). Recent data suggest that
MC-1R (Mandrika et al., 2005) and
MC-4R (Biebermann et al., 2003) form
dimers or oligomers. MC-1R dimeriza-
tion has various functional conse-
quences such as dominant-negative
effects, or modulation of pharmaco-
logical properties (Sa´nchez-Laorden
et al., 2006).
The MC-Rs signal primarily by cou-
pling to the heterotrimeric Gs protein,
which activates adenylate cyclase, thus
increasing cAMP (Figure 2). However,
MC-Rs may trigger additional signalling
pathways in some, but not all, cell
types. MC-3R activates the inositol
triphosphate and Ca2þ signalling sys-
tems (Konda et al., 1994; Kim et al.,
2002; Wachira et al., 2003). Coupling
to Ca2þ responses was also reported
for MC-5R (Hoogduijn et al., 2002),
Mc-1r, Mc-3r, Mc-4r, and Mc-5r
(Mountjoy et al., 2001), MC-4R (Saba-
tier et al., 2003), and MC-1R expressed
in keratinocytes (Elliott et al., 2004),
and melanoma cells (Eves et al., 2003).
MC-1R and Mc-1r (Sanchez-Mas et al.,
2004) display agonist independent ac-
tivity. This is consistent with an inverse
agonist behavior of ASP and accounts
for the direct actions of ASP in the
absence of MCs (Graham et al., 1997;
Sakai et al., 1997; Siegrist et al., 1997;
Suzuki et al., 1997; Ollmann et al.,
1998).
MC-R signalling is rapidly attenu-
ated within minutes of agonist expo-
sure. This homologous desensitization
has been reported for Mc-4r (Shinyama
et al., 2003), Mc-2r (Baig et al., 2001),
and Mc-1r and MC-1R in melanoma
cells (Sanchez-Mas et al., 2005a).
Desensitization of MC-1R is likely
mediated by phosphorylation by
GRK2 or GRK6, two members of the
G protein-coupled receptor kinase
family expressed in melanocytes
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Figure 1. Biosynthesis and biochemical structure of the natural MCs. (a) The natural MCs are classically
generated from POMC by the proteolytic action of prohormone convertase 1/3 and prohormone
convertase 2 together with its cofactor and chaperone 7B2 but furin convertase (FC) and PACE4 can also
cleave POMC. This processing yields MCs but also the endogenous opioids (a-, b-, and g-ED), which
do not bind to MC-Rs but to oipioid receptors, and the POMC fragments b- and g-lipotrophin (LPH)
and corticotropin-like intermediate lobe peptide (CLIP). (b) Further processing of a-MSH included
C-amidation and N-acetylation. The pharmacophore of a-MSH resides in the amino acids 4–10. For
many immunomodulatory actions of a-MSH, the C-terminal tripeptide of a-MSH, KPV, is also active.
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(Figure 2). Phosphorylation by GRKs is
often followed by internalization of
receptor-agonist complexes and may
trigger new signalling events (Luttrell
and Lefkowitz, 2002). Phosphorylation-
dependent internalization was demon-
strated for Mc-4r (Shinyama et al.,
2003), and probably occurs also
for MC-1R (Jime´nez-Cervantes and
Garcı´a-Borro´n, unpublished observa-
tions). This is consistent with reports on
internal MCs in melanoma cells
following their addition to the external
medium, and on the appearance of
acid-resistant binding (Varga et al.,
1976; Adams et al., 1993; Siegrist and
Eberle, 1993; Wong and Minchin, 1996;
Slominski et al., 2000a). The fate of
internalized complexes is uncertain, but
rapid translocation to lysosomes without
evidence of receptor recycling to the
plasma membrane has been reported
(Wong and Minchin, 1996). Since MC-
1R gene expression is upregulated by
the MCs (Slominski et al., 2000a), the
density of binding sites in pigment cells
continuously exposed to agonists may
depend on the balance between two
opposing effects that is, receptor seques-
tration on the one hand, and activation
of gene expression on the other. This
balance may vary between cell lines
accounting for the heterogeneity in the
final response (Siegrist et al., 1994).
Melanocortins – regulators of epidermal
and follicular melanocytes
There is strong evidence that MCs are
important regulators of mammalian
skin pigmentation (Abdel-Malek et al.,
1999; Slominski et al., 2005b). Indirect
evidence for such a role in man
originated from the observation that
skin pigmentation increases after sys-
temic administration of ACTH, a-MSH,
and b-MSH (Lerner and McGuire,
1961). Moreover, supraphysiological
blood levels of ACTH or a-MSH lead
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Figure 2. The MC-1R cycle and its regulation. Activatory and inhibitory events are shown in green and red, respectively, with a dashed line whenever they have
not yet been fully demonstrated. (1) Transcription of the MC-1R gene is stimulated by UV radiation, the melanocortins, IL-1a, and IL-1b, and inhibited by TNF-a,
TGF-b, and hydrogen peroxide. (2) The transcript is exported to the cytosol, where translation begins. The structure and properties of the transcript may be
influenced by the presence of agonists or antagonists. (3) The nascent protein associates with the endoplasmic reticulum, where translation resumes and
post-translational modifications take place. (4) The protein moves to the Golgi apparatus, where post-translational processing is completed. (5) Mature and
correctly folded receptor molecules are exported from the Golgi to the plasma membrane. Intracellular traffic of the protein is blocked or impaired by certain
mutations, leading to retention of the misfolded units. The exact site of retention remains to be determined, but the most likely possibility is the endoplasmic
reticulum. (6) Within the plasma membrane, the functional unit is likely a dimeric form activated by the MCs and inhibited by ASP. On agonist binding,
the receptor couples positively to adenylyl cyclase, via the heterotrimeric Gs protein. The active receptor is a substrate of GRK2 and GRK6 that phosphorylate
the receptor and block functional coupling. (7) The desensitized receptor and its ligand are internalized in endocytic vesicles. (8) The fate of the internalized
receptor remains to be determined, although current evidence suggests lysosomal degradation rather than resensitization and recycling to the plasma membrane.
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to hyperpigmentation in humans (cf
Slominski et al., 2000a, 2004b). Pa-
tients with POMC null mutations have
recently been described that display
the red hair and fair skin phenotype
(RHC phenotype) (Krude et al., 1998;
Krude and Gruters 2000). The unex-
pected finding of brown/black pigmen-
tation in POMC null mice (Yawsen
et al., 1999; Smart et al., 2003;
Slominski et al., 2005a) may indicate
that eumelanogenesis in these animals
is due either to sufficient basal activity
of the murine Mc-1r (Sanchez-Mas
et al., 2004) or to the existence of
non-MC pathway(s) that compensate
for MC deficiency, for example, bone
morphogenetic protein (Sharov et al.,
2005) and opioid signalling or other
pathways that modulate intracellular
PKA and PKC activity (Kauser et al.,
2004, 2005). In higher vertebrates,
various MC-1R mutants have been
unravelled, for example, the chestnut
coat color in horses or the blue variant
of the arctic fox (Andersson, 2003;
Vage et al., 2005) and in man several
MC-1R alleles are associated with the
RHC phenotype (Valverde et al., 1995;
Rees and Healy, 1997; Rees, 2000;
Sturm, 2002). The RHC alleles encode
proteins with varying degrees of func-
tional impairment, from modest de-
creases in agonist affinity or coupling
efficacy to nearly complete loss of
functional coupling (Frandberg et al.,
1998; Schio¨th et al., 1999; Scott et al.,
2002a; Leonard et al., 2003; Ringholm
et al., 2004). Aberrant traffic and
intracellular retention is a common
cause of MC-1R dysfunction associated
with the RHC phenotype (Beaumont
et al., 2005; Sa´nchez-Laorden et al.,
2006).
UV light is the major environmental
stimulus for MCs and MC-1R in the
epidermis. UVB light upregulates
ACTH/a-MSH and MC-1R in normal
epidermal melanocytes (Slominski and
Pawelek, 1998; Chakraborty et al.,
1999a). MC-1R expression is likewise
induced by UV light in normal human
keratinocytes (Chakraborty et al.,
1999b) and human epidermis in vivo
(Schiller et al., 2004). This UV light-
induced activation of POMC and
MC-1R promoters may be mediated
by p38 stress-activated kinase signalling
to upstream stimulating factor-1 (Corre
et al., 2004). Therefore, the inductive
effects of UV light on MCs and MC-1R
expression in epidermal cells in vitro
and in situ suggest that tanning is
dependent on activation of the a-MSH/
MC-1R system, as first proposed by
Pawelek and co-workers (Chakraborty
et al., 1999a). Regulation on MC-1R
expression by the MCs and other
paracrine effectors has been recently
reviewed (Slominski et al., 2000a). MC-
1R mRNA is upregulated by MCs in
normal human melanocytes (Funasaka
et al., 1998), and downregulated by
ASP (Scott et al., 2002b). A regulatory
mechanism based on ligand-dependent
modulations of the 50 untranslated
region of Mc-1r mRNA has been
reported (Rouzaud et al., 2003).
Among the cytokines and paracrine
factors produced in the skin, endothelin
1 (Scott et al., 2002b), IL-1a/b (Funasa-
ka et al., 1998) upregulate MC1R
mRNA in normal human melanocytes.
Two cytokines that suppress melano-
genesis, tumor necrosis factor-a (TNF-
a) (Martinez-Esparza et al., 1998) and
transforming growth factor-b (TGF-b)
(Martinez-Esparza et al., 1997), both
downregulate MC-1R expression in
normal human melanocytes (Funasaka
et al., 1998), and mouse melanoma
cells (Martinez-Esparza et al., 1999).
Low concentrations of hydrogen per-
oxide reversibly repress Mc-1r expres-
sion in mouse melanoma cells
(Jimenez-Cervantes et al., 2001). Hy-
drogen peroxide is a by-product of
melanogenesis and reactive oxygen
species are formed in UV light-irra-
diated skin (Nishigori et al., 2004).
Finally, early observations suggest that
certain melanogenic intermediates may
act as chemical signals to upregulate
the expression and activity of MC-1Rs
(cf Slominski et al., 2004b).
In rodents, a-MSH stimulates folli-
cular melanogenesis by preferentially
increasing the synthesis of eumelanin
over pheomelanin (Geschwind et al.,
1972; Tamate and Takeuchi, 1984;
Eberle, 1988; Granholm and Van
Amerongen, 1991), in large part via
the stimulation of tyrosinase activity at
the transcriptional, translational or
post-translational levels (Burchill and
Thody, 1986; Burchill et al., 1988). In
human epidermal melanocytes, a-MSH
and ACTH stimulate melanogenesis,
dendricity, and proliferation via action
at the MC-1R (Hunt et al., 1994a, b, c;
Abdel-Malek et al., 1995; Suzuki et al.,
1996; Wakamatsu et al., 1997; Tsatma-
li et al., 1999a, 2002), mediated pre-
dominately via the cAMP second
messenger system (Busca and Ballotti,
2000).
Recently, involvement of the MC
system was detected in the human hair
follicle in situ and in follicular cell
subpopulations in vitro (Bo¨hm et al.,
2005a; Kauser et al., 2005). These
findings are in agreement with the
previous detection of POMC mRNA in
these hair follicle cell subpopulations
(Kauser et al., 2003, 2004). Expression
of POMC peptides and MC-1R appears
to be highly coordinated during the
hair cycle, but perhaps a-MSH and
ACTH are not directly involved in the
maintenance of melanogenesis during
the growth or anagen phase of the hair
cycle (Slominski et al., 1992; Ermak
et al., 1997). This heterogeneous pat-
tern of a-MSH and ACTH expression
has also been reported for corticotro-
pin-releasing hormone and the cortico-
tropin-releasing hormone receptor-1
(Ito et al., 2004, 2005; Slominski
et al., 2004a) – the chief regulator of
pituitary POMC gene expression and
the production and secretion of POMC
peptides (Slominski et al., 2000a,
2004a). The expression of a-MSH and
ACTH may be associated with the
ability of some hair bulb melanocytes
to survive the apoptosis driven catagen
process (Tobin et al., 1999; Commo
and Bernard, 2000; Tobin and Paus,
2001). Indeed, in humans, ACTH may
stimulate and/or prolong anagen, as
overproduction of ACTH or therapeutic
administration of ACTH causes ac-
quired hypertrichosis associated with
increased pigmentation (Paus, 1998).
Further support for a role of MCs in
melanocyte function comes from the
observation that both a-MSH and
ACTH 1–17 increase melanogenesis,
dendricity, and proliferation in follicu-
lar melanocytes (Kauser et al., 2005).
ACTH 1–17 is more effective at indu-
cing melanogenesis in follicular mela-
nocytes than a-MSH, while a-MSH is
most potent at inducing melanocyte
www.jidonline.org 1969
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dendricity. This observation concurs
with recent findings that ACTH 1–17
is more potent than a-MSH at activating
the MC-1R and stimulating epidermal
melanogenesis (Tsatmali et al., 1999b).
Moreover, the melanogenic and den-
dritogenic effects of a-MSH and ACTH
1–17 in follicular melanocytes appear
to correlate positively with increasing
hair color, supporting earlier data
showing that a-MSH binding sites
maybe linked to hair color (Nanninga
et al., 1991).
Melanocortins and lipid synthesis in
human sebocytes
A role for a-MSH as a ‘‘sebotrophin’’
has been postulated decades ago based
on its effect on the rat preputial gland
(Thody and Shuster, 1973; Thody and
Shuster, 1989), but only recently it was
shown that human sebocytes express
MC-Rs. Accordingly, MC-5R transcripts
were detected in micro-dissected se-
baceous glands derived from facial
human skin and MC-5R immunoreac-
tivity in human facial sebaceous glands
in situ (Thiboutot et al., 2000; Hatta
et al., 2001). Since sebaceous glands of
mice also express Mc-5r and targeted
disruption of it results in reduced water
repulsion and sebum secretion (Chen
et al., 1997), it is possible that MC-5R
in man likewise mediates sebogenesis.
However, we and others have detected
MC-1R in the immortalized human
sebocyte cell line SZ95 as well as in
primary human sebocytes (Bo¨hm et al.,
2002; Zhang et al., 2003). In primary
human sebocytes, MC-1R is signifi-
cantly higher expressed than MC-5R
while in SZ95 sebocytes MC-5R ex-
pression is undetectable (Bo¨hm et al.,
2002). Initial functional studies on
human sebocytes revealed that MC
peptides at 108 M increase lipid dro-
plet formation and NDP-a-MSH
furthermore stimulates squalene synth-
esis in these cells (Zhang et al., 2003).
Based on these findings, MCs released
upon psychoemotional stress may in-
fluence the course of acne vulgaris
(Zouboulis and Bo¨hm 2004). However,
since a-MSH also has anti-inflamma-
tory effects in sebocytes (Bo¨hm et al.,
2002), the precise role of MCs and its
receptors in human sebaceous gland
biology awaits further clarification.
Role of melanocortins in keratinocyte
biology
Less is known about the specific
influences of MCs on keratinocytes
compared to melanocytes. POMC,
ACTH, and a-MSH are expressed by
normal human epidermal keratinocytes
and are upregulated by UVB light in
vitro (Schauer et al., 1994), suggesting
a role of MCs in the tanning response
via a paracrine mechanism. The MC-
1R is expressed by normal human
epidermal and follicular keratinocytes,
HaCaT keratinocytes, and malignant
human keratinocytes (Luger et al.,
2000; Curry et al., 2001; Moustafa
et al., 2002; Kauser et al., 2005).
Moreover, UVB light and IL-1 are
potent upregulators of MC-1R expres-
sion in normal and malignant human
keratinocytes (Chakraborty et al.,
1999b; Luger et al., 2000).
Several lines of evidence suggest
that MCs are involved in proliferation
and differentiation of keratinocytes.
POMC expression is elevated during
tissue healing and regeneration (Slo-
minski et al., 1993). In normal inter-
follicular human epidermis, POMC
gene expression and a-MSH immunor-
eactivity is highest in the differentiated
cell layers of the human epidermis
(Nagahama et al., 1998; Kono et al.,
2001). Expression of POMC peptides
and its processing machinery also varies
depending on the follicular keratino-
cyte differentiation status (Kauser et al.,
2005). Functional experiments with
MSH peptides revealed modulatory
effects on keratinocyte proliferation in
the epidermis during the telogen phase
of the hair cycle, while inhibiting
proliferation during anagen (Slominski
et al., 1991). In HaCaT keratinocytes a-
MSH augmented proliferation (Orel
et al., 1997). In these cells, MC peptides
at 107–1015 M were able to modulate
intracellular levels of calcium, a key
regulator of keratinocyte differentiation
(Elliott et al., 2004). A calcium spike by
MC peptides at picomolar doses was
not observed in CHO cells stably
transfected with the MC-1R (Elliott
et al., 2004), suggesting another high-
affinity site for MC peptides in HaCaT
keratinocytes.
In addition to the above effects, MCs
have immunomodulatory actions in
human keratinocytes. Similarly to hu-
man epidermal melanocytes, melano-
ma cells (Haycock et al., 1999) and
dermal microvascular endothelial cells
(Kalden et al., 1999), a-MSH inhibits
NF-kB activation induced by pro-in-
flammatory stimuli in human epider-
mal keratinocytes, or HaCaT cells
(Brzoska et al., 1999; Moustafa et al.,
2002). a-MSH also suppressed glu-
tathione peroxidase activity after sti-
mulation with TNF-a or H2O2 in
HaCaT cells suggesting a protective
role for MCs against oxidative stress
induced by pro-inflammatory cytokines
(Haycock et al., 2000). Recently,
a-MSH was shown to reduce prosta-
glandin E2 production induced by TNF-
a in HaCaT keratinocytes (Nicolaou
et al., 2004). Since a-MSH induces IL-
10 expression by human keratinocytes
(Redondo et al., 1998), UVB light-
induced immunosuppression may be
mediated in part via MCs released by
the epidermis (Schiller et al., 2004).
a-MSH – a modulator of inflammatory
responses of the dermal endothelium
Specific and saturable binding sites for
a-MSH and MC-1R transcripts were
detected in cultured human dermal
microvascular endothelial cells (Hart-
meyer et al., 1997). Expression of the
MC-1R was upregulated in these cells
by IL-1b and by a-MSH itself. Interest-
ingly, a-MSH alone increased the ex-
pression of IL-8 and GROa in vitro
indicating that a-MSH under certain
conditions can also elicit pro-inflam-
matory effects (Scholzen et al., 1999).
A similar observation was made in
human dermal fibroblasts where a-MSH
increased IL-8 expression and release
(Bo¨hm et al., 1999a; Kiss et al., 1999).
On the other hand, a-MSH suppressed
IL-1b-induced IL-8 secretion in these
cells (Bo¨hm et al., 1999a) consistent
with its established anti-inflammatory
action. In vivo however a-MSH signifi-
cantly reduced lipopolysaccharide-
induced vascular hemorrhage (the
so-called Shwartzman reaction) and
suppressed expression of vascular cel-
lular adhesion molecule-1 and E-selec-
tion in situ (Scholzen et al., 2003). In
vitro expression of these adhesion
molecules as well as of intercellular
adhesion molecule-1was also sup-
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pressed by a-MSH at 108 and 10–12 M
in human dermal microvascular en-
dothelial cells stimulated with lipopo-
lysaccharide or TNF-a. These findings
highlight an anti-inflammatory activity
of a-MSH on the dermal endothelium
that may be exploited for future therapy
of vasculitis. Furthermore, a-MSH re-
leased by the endothelium itself during
inflammatory responses (Scholzen
et al., 2000) may help to maintain the
functional integrity of the endothelial–-
dermal interface, thereby limiting the
extent of endothelial damage during
vasculitis.
Fibroblasts –novel target cells for a-MSH
in the skin
A growing number of reports indicate
that human dermal fibroblasts are
target cells of a-MSH. Kiss et al.
(1995) initially reported a stimulatory
effect of a-MSH (106 and 108) in
adult human Dermal fibroblasts on
matrix metalloproteinase-1. Subse-
quent studies revealed the presence of
MC-1R transcripts, MC-1R immuno-
staining, and high-affinity binding sites
for a-MSH in human dermal fibroblasts
derived from newborn foreskin (Bo¨hm
et al., 2004). MC-1R transcripts were
also detectable in human adult dermal
fibroblasts, connective tissue sheath
fibroblasts of the hair follicle as well
as in dermal papilla cells in vitro (Bo¨hm
and Luger, 2004; Bo¨hm et al., 2005a).
Human dermal papilla cells, a specia-
lized myofibroblast cell type regulating
hair follicle activity, expressed both
MC-1R and MC-4R (Bo¨hm et al.,
2005a). Immunohistochemical studies
of nondiseased human skin have dis-
closed MC-1R immunoreactivity in
dermal fibroblasts situated in the peri-
adnexal connective tissue sheaths of
the hair follicles (Bo¨hm et al., 1999b,
2004) as well as in follicular dermal
papilla cells, which in addition ex-
pressed MC-4R (Bo¨hm et al., 2005a).
A role for a-MSH as a regulator of
the extracellular matrix of the skin is
supported by recent studies demon-
strating an effect of a-MSH on collagen
synthesis induced by TGF-b1, a key
profibrotic cytokine implicated in the
pathogenesis of fibrotic disorders in-
cluding systemic sclerosis. In vitro
a-MSH suppressed the TGF-b1-induced
expression of COL(I)a1,COL(I)a2 and
COL(III)a2 chains and of procollagen
type I-C-terminal peptide (PICP) by
human dermal fibroblasts (Bo¨hm
et al., 2004). The antagonistic effect of
a-MSH on TGF-b1-induced PICP was
abrogated by a synthetic peptide corre-
sponding to the cysteine-rich C-term-
inal domain of ASP. These data and the
stimulatory effect of a-MSH at 106 to
109 M on intracellular cAMP in human
dermal fibroblasts indicate that a-MSH
mediate its effects via the expressed
MC-1R. The functional relevance of the
above findings was supported using a
newborn mouse model in which der-
mal fibrosis was induced by repetitive
injections with high doses of TGF-b1.
a-MSH suppressed interstitial fibrosis
induced by TGF-b1 and reduced the
number of vimentin and a-smooth
muscle actin positive cells.
The activity of a-MSH on collagen
metabolism – in combination with its
anti-inflammatory actions – could be of
special value for the future therapy of
skin disorders where fibroblasts are
aberrantly activated. For example, en-
hanced expression of intercellular ad-
hesion molecule-1 has been reported in
fibroblasts from patients with systemic
sclerosis (Abraham et al., 1991), but
a-MSH can suppress its expression in
fibroblastic cells (Bo¨hm et al., 2005a;
Hill et al., 2006). The combined anti-
inflammatory and anti-fibrogenic activ-
ity of a-MSH may also be beneficial in
the treatment of inflammatory forms of
alopecia, for example, in scarring
alopecia but also in alopecia areata in
which a breakdown of the immune
privilege occurs (Paus et al., 2003).
Melanocortin receptor ligands and
human adipocytes
In the last years, enormous progress has
been made in dissecting the hypotha-
lamic MC system, its multiple interac-
tions with other neurohormones such
as AGRP as well as with adipogenic
hormones, and its role as a key
regulator of energy homeostasis and
food intake (Hoggard et al., 2004;
Cheung et al., 2005; Cone, 2005;
Della-Fera and Baile, 2005). Both
ACTH and a-MSH have been shown
to induce lipolysis in mice, rats, ham-
sters, guinea-pigs, and primates with
considerable species variability (Ng,
1990; Bousquet-Melou et al., 1995;
Boston, 1999). However, whether
MCs directly affect lipid metabolism
of human adipocytes is unclear. Sev-
eral investigators failed to detect a
lipolytic effect of MCs in human
adipose tissue or in ex vivo organ
cultures (Bousquet-Melou et al., 1995;
Kiwaki and Levine, 2003), while others
observed a lipolytic effect of 50 nM
ACTH in primary human adipocytes
(Xue et al., 1998). In murine adipo-
cytes, the lipolytic activity of ACTH
appears to be mediated via Mc-2r.
Mc-2r and to a lesser extent Mc-5r
RNA expression was detected in mur-
ine adipose tissue. In accordance with
these data, murine 3T3-L1 fibroblasts
express both Mc-2r and Mc-5r after in
vitro differentiation into adipocytes
(Boston and Cone, 1996). In the human
system, conflicting data have been
reported regarding the expression of
MC-Rs in adipose tissue (Chagnon
et al., 1997; Kiwaki and Levine, 2003;
Mynatt and Stephens, 2003). Of note,
in murine and human skin, MC-2R is
detectable (Slominski et al., 1996;
Ermak and Slominski, 1997).
Regarding ASP or its murine homo-
log agouti protein (AP), several studies
have demonstrated a regulatory action
of this MC-1R and MC-4R antagonist
on intracellular calcium in adipocytes
(Kim et al., 1997; Shi et al., 2000). AP
increased calcium in 3T3-L1 cells as
well as in HEK-293 cells transfected
with the MC-1R or MC-3R but not in
nontransfected cells. AP increased the
activity of fatty acid synthase, a key
lipogenic gene, in 3T3-L1 cells and in
human adipocytes (Claycombe et al.,
2000). Long-term treatment of primary
human adipocytes with 100 nM AP
inhibited basal lipolysis and blocked
ACTH-induced lipolysis. However, AP
also blocked lipolysis induced by for-
skolin suggesting that the anti-lipolytic
effect of AP not mediated by the
cognate MC-R expressed by human
adipocytes (Xue et al., 1998). Since
ASP is expressed in human adipose
tissue (Kwon et al., 1994; Wilson et al.,
1995) and most abundantly in mature
adipocytes (Xue and Zemel, 2000)
ASP may function as an endogenous
local modulator of lipid metabolism.
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Interestingly, ASP mRNA levels in
adipose tissue are elevated in patients
with type II diabetes (Smith et al.,
2003). Moreover, transgenic mice over-
expressing AP in adipose tissue suffer
from elevated body weight due to
increased fat mass, with accentuation
of the obesity when fed a high-fat diet
(Mynatt and Stephens, 2001, 2003).
Mast cells – integral players in the
cutaneous melanocortin system
More than 20 years ago, it was already
reported that very high doses of ACTH
and ACTH1-24 (103–106 M) induce a
histamine release in rat pleural and
peritoneal mast cells (Burt and Stan-
worth, 1983; Irman-Florjanc and Erja-
vec, 1984). a-MSH at subnanomolar
concentrations likewise was found to
act as a secretagogue in human skin
mast cells (Gru¨tzkau et al., 2000).
Whether this effect of a-MSH is MC-
R-mediated is unclear since the latter
authors did not detect a classical cAMP
response of the cells at doses sufficient
to activate the MC-1R and MC-5R, both
of which are expressed in human skin
mast cells and the human leukemic
mast cell line HMC-1 (Artuc et al.,
1999; Gru¨tzkau et al., 2000). In murine
bone marrow mast cells, a-MSH at
108 and 1010 M but not at 106 M,
however, increased intracellular cAMP
(Adachi et al., 1999). In contrast to the
human system, a-MSH was reported to
inhibit histamine release in murine
bone marrow mast cells (Adachi
et al., 1999) and to exert anti-inflam-
matory actions such as downmodula-
tion of the mRNA expression of IL-1b,
TNF-a and lymphotactin (Adachi et al.,
1999), suppression of serum-activated
lipopolysaccharide-induced NF-kB ac-
tivation, and intercellular adhesion
molecule-1 expression (Sarkar et al.,
2003). In human skin mast cells,
a-MSH did not affect the basal mRNA
levels of several proinflammatory cyto-
kines (Gru¨tzkau et al., 2000). It is
possible that the heterogeneous effects
of a-MSH on histamine release and
cytokine expression in murine and
human mast cells are due to species-
or tissue-specific differences or reflect
the individual experimental conditions.
Whether mast cells can generate MC
peptides remains to be shown. Mast
cell granules may interact with posi-
tively charged groups in the F(ab’)2
and/or Fc segments of utilized antibo-
dies via a cation-exchange mechanism
to yield false positive immunoreactivity
(Ruck et al., 1990). Thus, the initially
observed ACTH immunostaining in mast
cells of urticaria pigmentosa and other
neoplastic mast cell diseases (Horny
et al., 1987; Akiyama et al., 1991)
awaits further elucidation with current
biochemical and molecular tools.
a-MSH – a mediator of cytoprotection
Several lines of evidence suggest that
the cutaneous MC system may be part
of the innate host defence barrier that
ultimately protects the skin and the
underlying body against environmental
stress, including infectious agents,
proinflammatory, and genotoxic stimu-
li. Indeed, MCs induce melanogenesis
to prevent the generation of skin
cancer. Furthermore, a-MSH and re-
lated peptides were found to exhibit
antimicrobial actions (Cutuli et al.,
2000). More recently, we reported that
a-MSH is capable to protect melano-
cytes as well as nonmelanogenic cell
types of the skin from the most ubiqui-
tous of environmental stressor – UVB
(Bo¨hm et al., 2005b). The antiapoptotic
effect of a-MSH was linked to reduction
in cyclopyrimidine dimers, the major
UV-induced DNA photoproduct. The
antiapoptotic effects of a-MSH and the
reduction in UVB-induced cyclopyri-
midine dimers were not observed in
melanocytes expressing loss-of func-
tion mutation of MC-1R (Kadekaro
et al., 2005). Moreover, XPA fibroblasts
with defective nucleotide excision
repair were not protected from
UVB-induced apoptosis indicating that
a-MSH suppresses UVB-mediated
apoptosis via enhanced DNA repair
(Bo¨hm et al., 2005b). Mechanistically,
the protective activity of a-MSH against
UVB damage involves the inositol
triphosphate kinase-Akt pathway, phos-
phorylation of the microphthalmia-
related transcription factor, and the
antiapoptotic protein Bcl2 (Kadekaro
et al., 2005).
These data may explain the in-
creased incidence of cutaneous mela-
nomas in patients with loss of function
MC-1R, that is, in those individuals
with the RHC phenotype. In addition,
they support a concept in which
a-MSH acts as a regulator of functional
integrity of the epidermis and dermis
via protecting cells from cell death
induced by UVB or cytotoxic cytokines
(Hill et al., 2005). In the epidermis,
a-MSH may therefore maintain the
crucial pigment-producing function of
melanocytes, and via reducing UVB-
induced DNA damage it may enhance
genomic stability of both melanocytes
and keratinocytes.
Conclusion and future perspectives
Research in the last few years has
provided compelling evidence for a
much broader role of MC and their
receptors in cutaneous biology than
ever thought before (Figure 3). An
increasing number of MCR-related ge-
netic diseases and conditions, includ-
ing the RHC phenotype associated with
certain MC1R mutant alleles, are re-
lated to the retention within intra-
cellular compartments of misfolded
receptor molecules. Studies have de-
monstrated that cell permeant specific
ligands called pharmacological chaper-
ones can bind to the defective protein
and partially restore a transport-com-
petent conformation. It is likely that
pharmacological compounds belong-
ing to this new class of agents will be
developed and will find their place in
the treatment of certain skin disorders.
The recent functional studies with
MC conducted so far have confirmed in
man many in vitro and in vivo observa-
tions in the rodent system, for example,
the sebotrophic effect of MCs on the
preputial gland of the rat, the central
role of MC-1R in coat color regulation
of mice, or the effect of AP on lipid
metabolism. On the other hand, other
novel biological activities of MC pep-
tides emerged by systematically screen-
ing the different cutaneous cell types
for MC-R expression and testing MCs
for biological effects on them. In
contrast to the large body of data on
the biological actions of MC peptides
in human pigment cells, research on
MC and MC-Rs in nonmelanocytic cell
types of the skin is still in its infancy.
However, the promising extra-pigmen-
tary actions of MCs, which are pre-
sented in this review, presage a broad
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future potential for MC peptides be-
yond pigmentation. In addition to the
potential use of MC peptides, or even
their antagonists, in the treatment of
individuals with disturbed sebum se-
cretion, the anti-inflammatory activity
of a-MSH combined with its antifibro-
genic effects may be particularly inter-
esting in the treatment of patients with
inflammatory and fibrotic diseases of
the skin including scleroderma, ecze-
ma, vasculitis, and alopecia areata to
mention only a few. Moreover, the
cytoprotective and DNA damage-redu-
cing effects of a-MSH may be of special
interest in diseases with increased
UV susceptibility, for example, in
patients with lupus erythematosus and
albinism, respectively. The authors of
this review are confident that the
cutaneous MC system will continue to
teach us further lessons in future, which
will attract more researchers to this
fascinating field and which will finally
help us to treat our patients more
efficiently.
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